302 related articles for article (PubMed ID: 12894234)
1. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
Kichina JV; Rauth S; Das Gupta TK; Gudkov AV
Oncogene; 2003 Jul; 22(31):4911-7. PubMed ID: 12894234
[TBL] [Abstract][Full Text] [Related]
2. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
3. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.
Satyamoorthy K; Chehab NH; Waterman MJ; Lien MC; El-Deiry WS; Herlyn M; Halazonetis TD
Cell Growth Differ; 2000 Sep; 11(9):467-74. PubMed ID: 11007451
[TBL] [Abstract][Full Text] [Related]
4. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
5. Dysfunction of the p53 tumor suppressor pathway in head and neck cancer.
Hoque MO; Kawamata H; Nakashiro K; Omotehara F; Hino S; Uchida D; Harada K; Begum NM; Yoshida H; Sato M; Fujimori T
Int J Oncol; 2002 Jul; 21(1):119-26. PubMed ID: 12063558
[TBL] [Abstract][Full Text] [Related]
6. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control.
Garkavtsev I; Grigorian IA; Ossovskaya VS; Chernov MV; Chumakov PM; Gudkov AV
Nature; 1998 Jan; 391(6664):295-8. PubMed ID: 9440695
[TBL] [Abstract][Full Text] [Related]
7. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
8. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.
Nourani A; Doyon Y; Utley RT; Allard S; Lane WS; Côté J
Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma.
Sun Y; Tran BN; Worley LA; Delston RB; Harbour JW
Invest Ophthalmol Vis Sci; 2005 May; 46(5):1561-4. PubMed ID: 15851551
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis.
Ho CK; Li G
Br J Dermatol; 2005 Nov; 153(5):900-10. PubMed ID: 16225598
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in p53-deficient human hepatoma cell line by wild-type p53 gene transduction: inhibition by antioxidant.
Lee KH; Kim KC; Jung YJ; Ham YH; Jang JJ; Kwon H; Sung YC; Kim SH; Han SK; Kim CM
Mol Cells; 2001 Aug; 12(1):17-24. PubMed ID: 11561726
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Bartussek C; Naumann U; Weller M
Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1.
Huang SM; Schönthal AH; Stallcup MR
Oncogene; 2001 Apr; 20(17):2134-43. PubMed ID: 11360197
[TBL] [Abstract][Full Text] [Related]
14. Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors.
Vieyra D; Senger DL; Toyama T; Muzik H; Brasher PM; Johnston RN; Riabowol K; Forsyth PA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5952-61. PubMed ID: 14676120
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma.
Soengas MS; Capodieci P; Polsky D; Mora J; Esteller M; Opitz-Araya X; McCombie R; Herman JG; Gerald WL; Lazebnik YA; Cordón-Cardó C; Lowe SW
Nature; 2001 Jan; 409(6817):207-11. PubMed ID: 11196646
[TBL] [Abstract][Full Text] [Related]
16. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
[TBL] [Abstract][Full Text] [Related]
17. H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism.
Delgado MD; Vaqué JP; Arozarena I; López-Ilasaca MA; Martínez C; Crespo P; León J
Oncogene; 2000 Feb; 19(6):783-90. PubMed ID: 10698496
[TBL] [Abstract][Full Text] [Related]
18. Retrovirally mediated wild-type p53 restores S-phase modulation without inducing WAF1 mRNA in breast carcinoma cells containing mutant p53.
Runnebaum IB; Wang S; Kreienberg R
J Cell Biochem; 1995 Dec; 59(4):537-44. PubMed ID: 8749722
[TBL] [Abstract][Full Text] [Related]
19. Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat.
Ryu J; Lee HJ; Kim KA; Lee JY; Lee KS; Park J; Choi SY
Mol Cells; 2004 Apr; 17(2):353-9. PubMed ID: 15179054
[TBL] [Abstract][Full Text] [Related]
20. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
